tiprankstipranks
Accolade Rises as Losses Narrow in Q1
Market News

Accolade Rises as Losses Narrow in Q1

Shares of the personalized healthcare company, Accolade (NASDAQ: ACCD) were on an upswing in pre-market trading at the time of writing on Friday as the company’s Q1 losses narrowed to $0.52 per share as compared to $4.92 per share in the same period last year while analysts were expecting the company to report a loss of $0.56 per share.

The company posted revenues of $93.2 million in Q1, up by 9% year-over-year as compared to consensus estimates of $93.4 million.

Looking forward, ACCD expects fiscal Q2 revenues between $93 million and $95 million while adjusted EBITDA is likely to be in the range of a loss of $11 million and $14 million. In FY24, the company has projected revenues between $410 million and $414 million while adjusted EBITDA is projected to be from a loss of $6 million and $12 million.

Analysts are cautiously optimistic about ACCD stock with a Moderate Buy consensus rating based on nine Buys and five Holds.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Accolade Rises as Losses Narrow in Q1
News On DemandStay up-to-date on market-moving news with a feed made just for youGet the App

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles